Onconetix (NASDAQ:ONCO – Get Free Report) issued its earnings results on Thursday. The company reported $21.25 earnings per share for the quarter, reports. The company had revenue of $0.10 million for the quarter.
Onconetix Stock Down 24.9%
ONCO opened at $4.73 on Friday. The business has a 50 day simple moving average of $6.11 and a two-hundred day simple moving average of $25.39. Onconetix has a one year low of $4.27 and a one year high of $1,190.00.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Onconetix to a “hold” rating in a report on Saturday.
About Onconetix
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Read More
- Five stocks we like better than Onconetix
- Stock Splits, Do They Really Impact Investors?
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
- How to Calculate Retirement Income: MarketBeat’s Calculator
- MarketBeat Week in Review – 06/09 – 06/13
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- IBM Up 10 Days in a Row: What’s Driving the Winning Streak?
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
